These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35774905)

  • 1. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
    Sarfraz N; Okuampa D; Hansen H; Alvarez M; Cornett EM; Kakazu J; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(3):34222. PubMed ID: 35774905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications.
    Thorpy MJ; Bogan RK
    Sleep Med; 2020 Apr; 68():97-109. PubMed ID: 32032921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the treatment of narcolepsy: clinical efficacy of pitolisant.
    Calik MW
    Nat Sci Sleep; 2017; 9():127-133. PubMed ID: 28490912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.
    Meskill GJ; Davis CW; Zarycranski D; Doliba M; Schwartz JC; Dayno JM
    CNS Drugs; 2022 Jan; 36(1):61-69. PubMed ID: 34935103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating pitolisant as a narcolepsy treatment option.
    de Biase S; Pellitteri G; Gigli GL; Valente M
    Expert Opin Pharmacother; 2021 Feb; 22(2):155-162. PubMed ID: 32941089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility.
    Guevarra JT; Hiensch R; Varga AW; Rapoport DM
    Nat Sci Sleep; 2020; 12():709-719. PubMed ID: 33117007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review.
    Fabara SP; Ortiz JF; Anas Sohail A; Hidalgo J; Altamimi A; Tama B; Patel UK
    Cureus; 2021 Jul; 13(7):e16095. PubMed ID: 34345566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
    Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
    Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitolisant: A Review in Narcolepsy with or without Cataplexy.
    Lamb YN
    CNS Drugs; 2020 Feb; 34(2):207-218. PubMed ID: 31997137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitolisant for treating patients with narcolepsy.
    Li S; Yang J
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):79-84. PubMed ID: 31937172
    [No Abstract]   [Full Text] [Related]  

  • 11. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
    Dauvilliers Y; Bassetti C; Lammers GJ; Arnulf I; Mayer G; Rodenbeck A; Lehert P; Ding CL; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2013 Nov; 12(11):1068-75. PubMed ID: 24107292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
    Dauvilliers Y; Lecendreux M; Lammers GJ; Franco P; Poluektov M; Caussé C; Lecomte I; Lecomte JM; Lehert P; Schwartz JC; Plazzi G
    Lancet Neurol; 2023 Apr; 22(4):303-311. PubMed ID: 36931805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach.
    Lehert P; Szoeke C
    Drugs Context; 2020; 9():. PubMed ID: 32699548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recently Approved and Upcoming Treatments for Narcolepsy.
    Thorpy MJ
    CNS Drugs; 2020 Jan; 34(1):9-27. PubMed ID: 31953791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies.
    Davis CW; Kallweit U; Schwartz JC; Krahn LE; Vaughn B; Thorpy MJ
    Sleep Med; 2021 May; 81():210-217. PubMed ID: 33721598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy.
    Romigi A; Vitrani G; Lo Giudice T; Centonze D; Franco V
    Drug Des Devel Ther; 2018; 12():2665-2675. PubMed ID: 30214155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study.
    Triller A; Pizza F; Lecendreux M; Lieberich L; Rezaei R; Pech de Laclause A; Vandi S; Plazzi G; Kallweit U
    Sleep Med; 2023 Mar; 103():62-68. PubMed ID: 36758348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances in treatment of narcolepsy].
    Xu Q; Lou G; Wang T; Zhang L
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 49(4):419-424. PubMed ID: 32985153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Narcolepsy.
    Barateau L; Lopez R; Dauvilliers Y
    Curr Treat Options Neurol; 2016 Oct; 18(10):43. PubMed ID: 27549768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy.
    Pérez-Carbonell L
    Curr Treat Options Neurol; 2019 Nov; 21(11):57. PubMed ID: 31713736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.